← GLP-1 receptor agonists × glycemic control

SynthesisDiabetes, obesity & metabolism2017

Glucagon-like peptide-1 receptor agonists compared with basal insulins for the treatment of type 2 diabetes mellitus: a systematic review and meta-analysis.

Sonal Singh et al.PubMed ↗Full text ↗Publisher ↗

  • Exenatide long acting release (LAR)looks good hereLower hemoglobin A1c.Randomised, small.
  • Dulaglutidelooks good hereLower hemoglobin A1c.Randomised, small.
  • Liraglutideno clear effectNo clear effect on hemoglobin A1c.Nothing cleared the noise.
  • Exenatideno clear effectNo clear effect on hemoglobin A1c.Nothing cleared the noise.

What the trial testedrandomised · 2017

Randomised vs basal insulins

Probably lowered hemoglobin A1c

−0.31percentage points−0.42 to −0.19

exenatide long acting release (LAR) vs basal insulins

As reported

difference −0.31 %, 95% CI −0.42 to −0.19

Randomised vs basal insulins

Probably lowered hemoglobin A1c

−0.39percentage points−0.49 to −0.29

dulaglutide vs basal insulins

As reported

difference −0.39 %, 95% CI −0.49 to −0.29

Range includes no effect

No clear effect on hemoglobin A1c

+0.06percentage points−0.06 to +0.18

liraglutide vs basal insulins

As reported

difference 0.06 %, 95% CI −0.06 to 0.18

Range includes no effect

No clear effect on hemoglobin A1c

+0.01percentage points−0.11 to +0.13

exenatide vs basal insulins

As reported

difference 0.01 %, 95% CI −0.11 to 0.13

Who was studied, and how

6,000people in the Effectiveness and Persistence of Therapy With GLP-1 Receptor Agonists in Clinical Practice. A Multicenter Retrospective Study trial, from 2018
of them with type 2 diabetes, in this paper

The trial randomly assignedassigned by chance

exenatide long acting release (LAR)
basal insulins

Probably lowered hemoglobin A1c−0.31

randomised

The trial randomly assignedassigned by chance

dulaglutide
basal insulins

Probably lowered hemoglobin A1c−0.39

randomised

the abstract, start to end

… reductions vs basal insulins (exenatide: -0.31% [95% confidence interval -0.42, -0.19], dulaglutide: -0.39% [-0.49, -0.29]) whilst once-daily liraglutide and twice-daily exenatide did not (liraglutide: 0.06% [-0.06, 0.18], exenatide: 0.01% [-0.11, 0.13]).

← favours treatmentfavours comparator →
could be chance
Hemoglobin A1c (HbA1c)exenatide long acting release (LAR) vs basal insulins
−0.31−0.42 to −0.19
Hemoglobin A1c (HbA1c)dulaglutide vs basal insulins
−0.39−0.49 to −0.29
Hemoglobin A1c (HbA1c)liraglutide vs basal insulins
0.06−0.06 to 0.18
Hemoglobin A1c (HbA1c)exenatide vs basal insulins
0.01−0.11 to 0.13
GLP-1 receptor agonistsGlycemic control
1 / 4

61 papers cite itlatest 60 shown

2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
this paperpooled ittrialcites it

The trial

NCT039598656,000 enrolled2018
Full record →Abstract, authors, funding and every citing paper · PMID 27717130